Baader Bank Aktiengesellschaft Has $720,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Baader Bank Aktiengesellschaft grew its stake in Amgen Inc. (NASDAQ:AMGN) by 258.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,764 shares of the medical research company’s stock after buying an additional 1,993 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Amgen were worth $720,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in AMGN. Capital Performance Advisors LLP acquired a new position in Amgen in the 3rd quarter worth $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the third quarter valued at about $29,000. Matrix Trust Co acquired a new position in shares of Amgen during the third quarter worth about $36,000. Livelsberger Financial Advisory bought a new position in shares of Amgen during the third quarter worth about $56,000. Finally, Icon Wealth Advisors LLC grew its holdings in shares of Amgen by 3,955.0% during the third quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock worth $56,000 after buying an additional 169,748 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN opened at $284.02 on Friday. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a market cap of $152.67 billion, a P/E ratio of 36.37, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The business’s fifty day moving average is $271.35 and its 200-day moving average is $304.99.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period last year, the firm earned $4.96 EPS. Sell-side analysts expect that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is presently 115.24%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research report on Tuesday, October 22nd. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Wells Fargo & Company lowered their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research report on Friday, January 10th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.